Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules

Competing Interest Statement

Dr. MANTOVANI reports personal fees from Ventana, personal fees from Pierre Fabre, personal fees from Verily, personal fees from AbbVie, personal fees from Astra Zeneca, personal fees from Verseau Therapeutics, personal fees from Compugen, personal fees from Myeloid Therapeutics, personal fees from Third Rock Venture, personal fees from Imcheck Therapeutics, personal fees from Ellipses, grants from Novartis, personal fees from Novartis, personal fees from Roche, personal fees from Macrophage Pharma, personal fees from BiovelocIta, personal fees from Merck, personal fees from Principia, other from Cedarlane Laboratories Ltd, other from HyCult Biotechnology, other from eBioscience, other from Biolegend, other from ABCAM Plc, other from Novus Biologicals, other from Enzo Life (ex Alexis Corp.), other from Affymetrix, personal fees from BMS, personal fees from Johnson&Johnson, outside the submitted work; In addition, Dr. MANTOVANI has a patent WO2019057780 "Anti-human migration stimulating factor (MSF)and uses thereof" issued, a patent WO2019081591 "NK or T cells and uses thereof" issued, a patent WO2020127471 "Use of SAP for the treatment of Euromycetes fungi infections" issued, and a patent EP20182181.6 "PTX3 as prognostic marker in Covid-19" pending. A.M., C.G. and B.B. are inventors of a patent (EP20182181) on PTX3 and obtain royalties on related reagents; A.M., C.G., B.B. and E.V. are inventors of a patent (102021000002738) on MBL. The other authors declare no competing interests.

Funding Statement

This work was supported by a philanthropic donation by Dolce & Gabbana fashion house (to A.M., C.G., E.V.), by the Italian Ministry of Health for COVID-19 (to A.M. and C.G.), the Italian Ministry of University and Research (to P.I.), by the Department of Excellence project PREMIA (PREcision MedIcine Approach: bringing biomarker research to clinic, to P.I.).We also thank the generous contribution of Banca Intesa San Paolo, and AMAF Monza ONLUS and AIRCS for the unrestricted research funding.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The collection of bronchial epithelial cells and their study to investigate airway epithelium physiopathology were specifically approved by the Ethics Committee of the Istituto Giannina Gaslini following the guidelines of the Italian Ministry of Health (registration number: (ANTECER, 042-09/07/2018). Each patient provided informed consent to the study using a form that was also approved by the Ethics Committee. Approvals for the genetical studies were obtained from the relevant ethics committees (Humanitas Clinical and Research Center, reference number, 316/20; the University of Milano Bicocca School of Medicine, San Gerardo Hospital, reference number, 84/2

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes